Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR7280 in Controlled Ovarian Hyperstimulation for ART
CTR20212511Phase 2Completed
- Sponsor
- Hengrui Therapeutics
- Start
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of SHR7280 in female infertility, Premature luteinizing hormone surge, sponsored by Hengrui Therapeutics. Started Oct 2021; status: completed.
02
Drugs
SHR7280
03
Conditions
female infertilityPremature luteinizing hormone surge
Beyond the preview
Go deeper on CTR20212511.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212511.